Advanced Cancer Clinical Trials in Nashville, Tennessee

7 studies are recruiting for advanced cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Center, Nashville, Tennessee

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

2. An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

   This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee

   Locations

   19 in total

   Run by

   Pfizer

   See if you can join NCT07426757 on ClinicalTrials.gov

3. A Study of PHN-012 in Patients With Advanced Solid Tumors

   This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   PHN-012-001 Site, Nashville, Tennessee

   Locations

   26 in total

   Run by

   Pheon Therapeutics

   See if you can join NCT07127874 on ClinicalTrials.gov

4. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

5. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

   This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The st…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee

   Locations

   38 in total

   Run by

   Shanghai Allink Biotherapeutics Co., Ltd.

   See if you can join NCT06656390 on ClinicalTrials.gov

6. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

   This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

   Locations

   21 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT04900818 on ClinicalTrials.gov

7. Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

   RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosph…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

   Locations

   14 in total

   Run by

   Riboscience, LLC.

   See if you can join NCT05270213 on ClinicalTrials.gov